Selinexor Combination Ph 1 Study

Solid Tumor Malignancy Clinical Trial

Official title:
An Investigator Sponsored Phase I/II Study of Selinexor in Combination With Irinotecan in Adults With Solid Tumors

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05177276
Study type	Interventional
Source	Hackensack Meridian Health
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	September 2014
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03822117` - Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)	Phase 2
Completed	`NCT00647764` - Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas	Phase 1
Recruiting	`NCT05164016` - Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
Recruiting	`NCT05768269` - A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Completed	`NCT04847050` - A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy	Phase 2